Precigen claims breakthroughs in CAR T cell therapy manufacturing that will eventually allow cancer centers to enable treatments earlier and at a lower cost.
Chimeric antigen receptor (CAR) T cell therapy continues to change the cancer treatment paradigm, with four therapies, to date, approved in the US. While opportunities continue to emerge for new cancer targets, CAR T treatments, up to this point, are, however, associated with some major challenges.
Conventional CAR T cell therapies have shown remarkable responses in patients with Hematologic B cell cancer but they require intensive manufacturing, and their expense has also limited patient access to these novel precision medicines, says Dr Helen Sabzevari, CEO of Precigen.